News & Videos - ESTABLISHMENT LABS HLD.

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2023. First Quarter Highlights and Outlook Second quarter worldwide revenue of $48.6 million increased 18.0% year-over-year and was a new quarterly record. 2023 revenue guidance remains $200 million to $210 million, an increase of 24%...

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2023, after the market closes on Tuesday, August 8, 2023, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or (201) 689-8037...

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced the grand opening of the Sulàyöm Innovation Campus in the Coyol Free Zone, Costa Rica. The Sulàyöm Campus will support Establishment Labs’ continued global growth with additional capacity and capabilities in manufacturing, R&D, digital media, training, and medical education. The first...

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in two upcoming investor conferences. Juan José Chacón-Quirós, Chief Executive Officer and Founder, and Raj Denhoy, Chief Financial Officer, will participate in the 2023 Jefferies Healthcare Conference held June 7-9, 2023. Mr. Chacón-Quirós and Mr. Denhoy are scheduled...

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced it has received CE marking under the European Medical Device Regulation for the Motiva Injector ® , the Motiva ® Inflatable Balloon, and the Motiva ® Channel Dissector. “The approval in Europe of our minimally invasive tools is an important step in the evolution of plastic surgery,”...

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2023. First Quarter Highlights and Outlook First quarter worldwide revenue of $46.5 million increased 21.0% year-over-year and was a new quarterly record; excluding the impact of foreign currency changes, revenue growth in the first...

Establishment Labs Holdings Inc. (Nasdaq: ESTA) (the “Company”), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced the closing of its previously announced public offering of 1,265,000 common shares at $71.50 per share. This includes the exercise in full by the underwriters of their option to purchase up to 165,000 additional common shares. The gross proceeds to the Company were...

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2023 after the market closes on Monday, May 8, 2023, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or (201) 689-8037...

Establishment Labs Holdings Inc. (NASDAQ: ESTA) (the “Company”), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced the pricing of its public offering of 1,100,000 common shares at a price of $71.50 per share. The gross proceeds to Establishment Labs, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $78.7...

Establishment Labs Holdings Inc. (NASDAQ: ESTA) (the “Company”), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that it has commenced a public offering of its common shares, to be sold by the Company in a registered public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the common shares to be sold in the proposed...

Establishment Labs Holdings Inc. (NASDAQ: ESTA) (the “Company”), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced preliminary unaudited financial results for the first quarter of 2023. In the three months ended March 31, 2023, the Company’s revenue is expected to be approximately $46.5 million, as compared to $38.5 million for the three months ended March 31, 2022. As of March 31,...

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today noted the presentation of a study update on the Motiva US IDE Study. The update included three-year patient follow-up data for primary augmentation subjects. The Medical Director of the Study, Dr. Caroline Glicksman, who is also a Principal Investigator in the Study, presented the results today at...

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced the launch of Mia Femtech™ (“Mia ® ”) in Japan, marking the beginning of a new era in breast aesthetics. “In 2013, we recognized that traditional breast augmentation was not meeting the needs of most women in Japan. Now, a decade later, we are providing a solution. Our launch of Mia...

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in The Aesthetic Meeting 2023, which is being held April 19-23 in Miami, Florida. At the meeting, Dr. Caroline Glicksman, the Medical Director for and a Principal Investigator in the Motiva US IDE Study, will present an update on the clinical trial after completion of...

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced that it has surpassed three million Motiva ® devices in market. “Since its founding, Establishment Labs has been guided by one core principle: putting women at the center of everything we do,” said Juan José Chacón-Quirós, Establishment Labs CEO and Founder. “We let science, engineering,...

Establishment Labs Holdings Inc. (Nasdaq: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced it has entered into agreements with four partners in Europe and a second partner chain in Japan for Mia Femtech™ (“Mia®”). “Our global rollout of Mia Femtech continues, and we are pleased to announce our first European partners in Sweden, Switzerland, and Spain, as well as an...

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023, at 9:50 am Eastern Time. A live webcast of the presentation will be available on the...

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that it has submitted the fourth and final module of its modular submission to the FDA for premarket approval of Motiva Implants® in the United States. The company also provided unaudited financial results for the fourth quarter and full year ended December 31, 2022 and provided 2023...

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2022, after the market closes on Monday, February 27, 2023, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or (201)...

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced preliminary unaudited revenue for the three months and fiscal year ended December 31, 2022. Establishment Labs’ preliminary unaudited revenue for the fourth quarter of 2022 is expected to be in the range of $43.3 million to $44.3 million, an increase of 23% to 25% over the same period in...